Although there are no dedicated AML trials yet, the anti-CTL-4 antibody ipilimumab has been evaluated in patients with persistent or progressive hematologic malignancies, including AML, after allo-SCT [114]. This evidence concerns the gene SLC44A4 and acute myeloid leukemia.